Disease-modifying drugs and Parkinson's disease

被引：39

作者：

Allain, Herve ^{[2
]}

Bentue-Ferrer, Daniele ^{[2
]}

Akwa, Yvette ^{[1
]}

机构：

[1] Univ Paris Sud, INSERM, U788, Fac Med,UMR S788, F-94276 Le Kremlin Bicetre, France

[2] Fac Med, Lab Pharmacol Expt & Clin, F-35043 Rennes, France

来源：

PROGRESS IN NEUROBIOLOGY | 2008年 / 84卷 / 01期

关键词：

Parkinson's disease; neuroprotection; animal models; clinical trials; drugs;

D O I：

10.1016/j.pneurobio.2007.10.003

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Symptomatic medications, L-Dopa and dopaminergic agents, remain the only clinically pertinent pharmacological treatment proven effective and available for the large population of patients with Parkinson's disease. The challenge for the pharmaceutical industry is to develop disease-modifying drugs which could arrest, delay or at least oppose the progression of the specific pathogenic processes underlying Parkinson's disease. The purpose of this review, based on recent biological and genetic data to be validated with appropriate animal models, was to re-examine the putative neuroprotective agents in Parkinson's disease and discuss the development of new strategies with the ultimate goal of demonstrating neurocytoprotective activity in this neurodegenerative disease. Since guidelines for research on neurocytoprotective drugs remain to be written, innovation will be the key to success of future clinical trials. It is reasonable to expect that future advances in our understanding of the pathogenic processes of Parkinson's disease will open the way to new perspectives for the treatment of other neurodegenerative diseases. (C) 2007 Elsevier Ltd. All rights reserved.

引用

页码：25 / 39

页数：15

共 244 条

[11]

BEAL MF, 2002, ANN NEUROL, V51, pS110

[12]

Benamer HTS, 2000, MOVEMENT DISORD, V15, P692, DOI 10.1002/1531-8257(200007)15:4<692::AID-MDS1014>3.0.CO

[13]

2-V

[14] A CONTROLLED TRIAL OF RILUZOLE IN AMYOTROPHIC-LATERAL-SCLEROSIS [J].

BENSIMON, G ;

LACOMBLEZ, L ;

MEININGER, V ;

BOUCHE, P ;

DELWAIDE, C ;

COURATIER, P ;

BLIN, O ;

VIADER, F ;

PEYROSTPAUL, H ;

DAVID, J ;

MALOTEAUX, JM ;

HUGON, J ;

LATERRE, EC ;

RASCOL, A ;

CLANET, M ;

VALLAT, JM ;

DUMAS, A ;

SERRATRICE, G ;

LECHEVALLIER, B ;

PEUCH, AJ ;

NGUYEN, T ;

SHU, C ;

BASTIEN, P ;

PAPILLON, C ;

DURRLEMAN, S ;

LOUVEL, E ;

GUILLET, P ;

LEDOUX, L ;

ORVOENFRIJA, E ;

DIB, M .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (09) :585-591

[15] Monoamine oxidase B inhibitors - Current status and future potential [J].

BentueFerrer, D ;

Menard, G ;

Allain, H .

CNS DRUGS, 1996, 6 (03) :217-236

[16] Intersecting pathways to neurodegeneration in Parkinson's disease:: Effects of the pesticide rotenone on DJ-1, α-synuclein, and the ubiquitin-proteasome system [J].

Betarbet, R ;

Canet-Aviles, RA ;

Sherer, TB ;

Mastroberardino, PG ;

McLendon, C ;

Kim, JH ;

Lund, S ;

Na, HM ;

Taylor, G ;

Bence, NF ;

Kopito, R ;

Seo, BB ;

Yagi, T ;

Klinefelter, G ;

Cookson, MR ;

Greenamyre, JT .

NEUROBIOLOGY OF DISEASE, 2006, 22 (02) :404-420

[17] Chronic systemic pesticide exposure reproduces features of Parkinson's disease [J].

Betarbet, R ;

Sherer, TB ;

MacKenzie, G ;

Garcia-Osuna, M ;

Panov, AV ;

Greenamyre, JT .

NATURE NEUROSCIENCE, 2000, 3 (12) :1301-1306

[18] Animal models of Parkinson's disease [J].

Betarbet, R ;

Sherer, TB ;

Greenamyre, JT .

BIOESSAYS, 2002, 24 (04) :308-318

[19] Neuroprotection for Parkinson's disease: a call for clinically driven experimental design [J].

Bezard, E .

LANCET NEUROLOGY, 2003, 2 (07) :393-393

[20] Identification of the region of non-Aβ component (NAC) of Alzheimer's disease amyloid responsible for its aggregation and toxicity [J].

Bodles, AM ;

Guthrie, DJS ;

Greer, B ;

Irvine, GB .

JOURNAL OF NEUROCHEMISTRY, 2001, 78 (02) :384-395

← 1 2 3 4 5 6 7 8 9 10 →